Eli Lilly and Company (India) Pvt. Ltd. (“Lilly India”) has announced the launch of the additional indication for Ramiven® (abemaciclib), following approval from The Drug Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with hormone receptor (HR)positive, human epidermal growth factor receptor 2(HER2) negative, node-positive early breast cancer (EBC) at high risk of recurrence.
CDK 4/6 inhibitors are a class of medicines used to treat certain types of metastatic breast cancers. In India, over 50,000 patients are diagnosed with HR+/HER2- early breast cancer (EBC) every year. Close to 30% of EBC patients with high-risk clinical or pathological features experience recurrence or metastasis despite receiving standard therapy.
Vineet Gupta, Managing Director, Eli Lilly and Company – India & India Subcontinent, said, “Breast cancer is the cancer which is most prevalent amongst women in India. It significantly impacts the quality of life of survivors and their families, who live with the fear of recurrence. The approval of Ramiven® for treatment of Early Breast Cancer brings more optimism by providing a new treatment option to the healthcare professionals for their patients.”
Ramiven is already approved for the treatment of certain types of HR+ HER2- advanced or metastatic breast cancer.
Ramiven is a prescription drug to be used only on the advice of an oncologist and under medical supervision. It is available in tablet strengths of 200 mg, 150 mg, 100 mg, and 50 mg.